Paydirt
FP
Insider

Frazier Life Sciences XI, L.P.

10% owner

Frazier Life Sciences XI, L.P. (10% owner) filed 1 Form 4 report as a reporting entity in the trailing twelve months (1 purchase, 0 sales), most often in Attovia Therapeutics, Inc. Common Stock (ATTO). Across 1 priced purchase filing, the average 21-session return was +9.8% from execution and +9.8% from disclosure (delay-adjusted; derived). The largest single filing was $10.0M of ATTO (588,235 sh × $17.00, as filed), executed Aug 6.

Add to watchlist
Return, ttmiAverage return per filing, trailing twelve months
+9.8%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+9.8%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
0d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$10.0M
shares × price, as filed
Last traded
Aug 6
Filed Aug 6
Open performance
Volume by month
$10.0M$5.0M$0Oct 2024Apr 2025Oct 2025Apr 2026Aug 2026 · buys $10.0M
Buys $10.0M Sells $0

Shares × price, as filed · by filing month · past 24 months

Sectors filed on
Not on file 1 filing

Sector per market data · by filing · past 12 months

Most traded names
ATTO Attovia Therapeutics, Inc. Common Stock ATTO · 1 buy · 0 sells 1 filing
Recent filings
ATTOPURCHASE Attovia Therapeutics, Inc. Common Stock View filing → $10.0M
588,235 sh × $17.00
Exec Aug 6
Filed Aug 6 · 5:35 PM ET